Endometrial cancer is a type of cancer that begins in the inner lining of the uterus—known as the endometrium. The ...

It also brings the UK as a whole into line with Scotland, which backed the combination for advanced or recurrent endometrial cancer in October 2022. When diagnosed and treated early, endometrial ...

In the U.S., Keytruda, also known as pembrolizumab, is approved for certain cases of endometrial carcinoma as a late-line option.

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

The following is a summary of “Facilitators and Barriers to Acceptability of a Biopsy-First Approach in the Diagnostic ...

Chemotherapy-based regimens, including in combination with immunotherapy, are a standard first-line therapy for inoperable stage III/IV or recurrent endometrial cancer. Christian Marth ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.